Braveheart Bio, Inc. (NASDAQ:BRVE)
| Market Cap | 1.55B+21.8% |
| Revenue (ttm) | n/a |
| Net Income | n/a |
| EPS | n/a |
| Shares Out | 70.65M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 224,088 |
| Open | 21.00 |
| Previous Close | 21.07 |
| Day's Range | 20.37 - 22.18 |
| 52-Week Range | 18.00 - 32.00 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | 45.25(+105.82%) |
| Earnings Date | n/a |
Braveheart Bio, Inc. has a live Insider Score.
Scored on 10 qualifying trades from 8 insiders in the last 90 days.
About BRVE
Braveheart Bio, Inc. engages in the development of therapeutics to treat hypertrophic cardiomyopathy. Its lead product candidate is BHB-1839 which is a small-molecule cardiac myosin inhibitor. The company was founded on May 13,2024 and is headquartered in San Francisco, CA.
What Are Insiders Doing?
View the trades behind this meter — each links to its SEC Form 4 →
Open-market Form 4 purchases (code P) vs sales (code S) on file for this company. Grants, option exercises and tax withholdings are excluded. Informational only.
$BRVE stock is featured in our Insider Score Rankings, and Insider Trades datasets.
→ All Stock ListsRecently reported changes in BRVE holdings by institutional investors
Latest 0 13F filings · Source: SEC EDGAR
View all institutional owners →Insider Trading
Quarterly net insider trading by BRVE's directors and management
Source: SEC EDGAR (Form 4)
Corporate Lobbying
BRVE Estimated quarterly lobbying spending
Source: U.S. Senate LDA
BRVE Revenue by Segment
| Segment | Revenue | % of All |
|---|---|---|
| Personnel-related | $5.32M | 59.91% |
| Other | $2.55M | 28.68% |
| Other income | $894.00K | 10.06% |
| Facilities | $119.00K | 1.34% |
As of: Q2 2026 (Jun 30, 2026) · Source: SEC EDGAR (10-Q)
U.S. Patents
New BRVE patent grants
Source: USPTO Open Data Portal
Government Contracts
Estimated quarterly amount awarded to BRVE from public contracts
Source: USAspending.gov
Top ETF Holders
ETFs with the largest estimated holdings in BRVE
| ETF | Est. Holding Size |
|---|---|
| SCHASchwab U.S. Small-Cap ETF | $2.69M |
| VTIVanguard Morningstar Total Stock Market ETF | $1.10M |
| VXFVanguard Extended Market ETF | $414.94K |
| ONEQFidelity Nasdaq Composite Index ETF | $403.20K |
| SCHBSchwab U.S. Broad Market ETF | $331.60K |
| FMEDFidelity Disruptive Medicine ETF | $299.14K |
Estimated from each fund’s disclosed top holdings × AUM
BRVE Insider Score
Our composite score: insider buying, sector, volume, tone & dilution
Bull Case vs Bear Case
AI-generated from BRVE’s recent data — informational, not investment advice
Insider Score
Our 0–100 Insider Score and the signals behind it.
The live Insider Score and its full factor breakdown are included with Insider Access.
Unlock Insider Score